Literature DB >> 19874804

NT79: A novel neurotensin analog with selective behavioral effects.

Mona Boules1, Yanqi Liang, Siobhan Briody, Tomofumi Miura, Irfan Fauq, Alfredo Oliveros, Mina Wilson, Shaheen Khaniyev, Katrina Williams, Zhimin Li, Yanfei Qi, Michael Katovich, Elliott Richelson.   

Abstract

Neurotensin, a tridecapeptide, is widely distributed in the brain and gastrointestinal tract. It possesses analgesic, hypothermic, and antipsychotic-like properties. Neurotensin's effects are mediated mainly through two receptor subtypes, NTS1 and NTS2. Activation of NTS1 has been implicated in most of the pharmacological effects of neurotensin but is associated with hypothermia and hypotension. We report on a novel neurotensin analog with higher selectivity to NTS2, namely, NT79, which exhibits selective behavioral effects. NT79 was tested in animal models for pain (thermal-hot plate test; visceral-acetic acid-induced writhing test), and in animal models that are predictive of antipsychotic-like effects (apomorphine-induced climbing; d-amphetamine-induced hyperactivity; disruption of prepulse inhibition). Its effects on body temperature and on blood pressure were also determined. Neurochemical changes in extracellular neurotransmitters were measured using in vivo microdialysis while the rats were simultaneously evaluated for acetic acid-induced writhing with and without pretreatment with NT79. Binding data at molecularly cloned hNTS1 and hNTS2 suggest selectivity for hNTS2. NT79 blocked the acetic acid-induced writhing with an ED(50) of 0.14 microg/kg while having no effect on thermal nociception. The writhing was paralleled by an increase in 5-HT which was attenuated by NT79. NT79 demonstrated antipsychotic-like effects by blocking apomorphine-induced climbing, d-amphetamine-induced hyperactivity, and reducing d-amphetamine- and DOI-induced disruption of prepulse inhibition. Uniquely, it caused no significant hypothermia and was without effect on blood pressure. NT79, with its higher selectivity to NTS2, may be potentially useful to treat visceral pain, and psychosis without concomitant side effects of hypothermia or hypotension.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19874804      PMCID: PMC2792000          DOI: 10.1016/j.brainres.2009.10.050

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  71 in total

1.  Receptor mediation of 5-HT-induced inflammation and nociception in rats.

Authors:  K J Sufka; F M Schomburg; J Giordano
Journal:  Pharmacol Biochem Behav       Date:  1992-01       Impact factor: 3.533

2.  Structure and functional expression of the cloned rat neurotensin receptor.

Authors:  K Tanaka; M Masu; S Nakanishi
Journal:  Neuron       Date:  1990-06       Impact factor: 17.173

3.  In vivo neurochemical and behavioural effects of intracerebrally administered neurotensin and D-Trp11-neurotensin on mesolimbic and nigrostriatal dopaminergic function in the rat.

Authors:  A P Ford; C A Marsden
Journal:  Brain Res       Date:  1990-11-26       Impact factor: 3.252

4.  Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs.

Authors:  B P Richardson; G Engel; P Donatsch; P A Stadler
Journal:  Nature       Date:  1985 Jul 11-17       Impact factor: 49.962

5.  Assessment of dopamine autoreceptor agonist properties of apomorphine, (+)-3-PPP and (-)-3-PPP by recording of yawning behaviour in rats.

Authors:  L Ståhle; U Ungerstedt
Journal:  Eur J Pharmacol       Date:  1984-02-17       Impact factor: 4.432

6.  Antiparkinson-like effects of neurotensin in 6-hydroxydopamine lesioned rats.

Authors:  F B Jolicoeur; R Rivest; S St-Pierre; A Drumheller
Journal:  Brain Res       Date:  1991-01-11       Impact factor: 3.252

7.  SCH 23390 dissociated from conventional neuroleptics in apomorphine climbing and primate acute dyskinesia models.

Authors:  S Gerhardt; R Gerber; J M Liebman
Journal:  Life Sci       Date:  1985-12-23       Impact factor: 5.037

8.  Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing.

Authors:  P W Kalivas; C B Nemeroff; A J Prange
Journal:  Neuroscience       Date:  1984-04       Impact factor: 3.590

9.  The rat paw formalin test: comparison of noxious agents.

Authors:  Helen Wheeler-Aceto; Frank Porreca; Alan Cowan
Journal:  Pain       Date:  1990-02       Impact factor: 6.961

10.  Blockade of the flare response to intradermal 5-hydroxytryptamine in man by MDL 72.222, a selective antagonist at neuronal 5-hydroxytryptamine receptors.

Authors:  J M Orwin; J R Fozard
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more
  19 in total

1.  The neurotensin-1 receptor agonist PD149163 inhibits conditioned avoidance responding without producing catalepsy in rats.

Authors:  Elizabeth N Holly; Bree Ebrecht; Adam J Prus
Journal:  Eur Neuropsychopharmacol       Date:  2011-01-28       Impact factor: 4.600

2.  Modifications at Arg and Ile Give Neurotensin(8-13) Derivatives with High Stability and Retained NTS1 Receptor Affinity.

Authors:  Lisa Schindler; Günther Bernhardt; Max Keller
Journal:  ACS Med Chem Lett       Date:  2019-05-10       Impact factor: 4.345

3.  Effects of neurotensin-2 receptor deletion on sensorimotor gating and locomotor activity.

Authors:  David Feifel; Zhen Pang; Zheng Pang; Paul D Shilling; Gilia Melendez; Rudy Schreiber; Donald Button
Journal:  Behav Brain Res       Date:  2010-04-21       Impact factor: 3.332

4.  The role of endogenous neurotensin in psychostimulant-induced disruption of prepulse inhibition and locomotion.

Authors:  Ricardo Cáceda; Elisabeth B Binder; Becky Kinkead; Charles B Nemeroff
Journal:  Schizophr Res       Date:  2011-11-21       Impact factor: 4.939

5.  The role of NTS2 in the development of tolerance to NT69L in mouse models for hypothermia and thermal analgesia.

Authors:  Kristin E Smith; Mona Boules; Katrina Williams; Abdul H Fauq; Elliott Richelson
Journal:  Behav Brain Res       Date:  2011-06-21       Impact factor: 3.332

6.  Effect of amphetamine on extracellular concentrations of amino acids in striatum in neurotensin subtype 1 and 2 receptor null mice: a possible interaction between neurotensin receptors and amino acid systems for study of schizophrenia.

Authors:  Zhimin Li; Yanqi Liang; Mona Boules; Andres Gordillo; Elliott Richelson
Journal:  Neuropharmacology       Date:  2010-03-01       Impact factor: 5.250

7.  The amide linker in nonpeptide neurotensin receptor ligands plays a key role in calcium signaling at the neurotensin receptor type 2.

Authors:  James B Thomas; Angela M Giddings; Srinivas Olepu; Robert W Wiethe; Keith R Warner; Philippe Sarret; Jean-Michel Longpre; Scott P Runyon; Brian P Gilmour
Journal:  Bioorg Med Chem Lett       Date:  2015-04-03       Impact factor: 2.823

8.  Identification of N-{[6-chloro-4-(2,6-dimethoxyphenyl)quinazolin-2-yl]carbonyl}-l-leucine (NTRC-808), a novel nonpeptide chemotype selective for the neurotensin receptor type 2.

Authors:  James B Thomas; Angela M Giddings; Srinivas Olepu; Robert W Wiethe; Danni L Harris; Sanju Narayanan; Keith R Warner; Philippe Sarret; Jean-Michel Longpre; Scott P Runyon; Brian P Gilmour
Journal:  Bioorg Med Chem Lett       Date:  2014-11-24       Impact factor: 2.823

Review 9.  Antipsychotic inductors of brain hypothermia and torpor-like states: perspectives of application.

Authors:  Yury S Tarahovsky; Irina S Fadeeva; Natalia P Komelina; Maxim O Khrenov; Nadezhda M Zakharova
Journal:  Psychopharmacology (Berl)       Date:  2016-12-08       Impact factor: 4.530

10.  Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties.

Authors:  Michel Demeule; Nicolas Beaudet; Anthony Régina; Élie Besserer-Offroy; Alexandre Murza; Pascal Tétreault; Karine Belleville; Christian Ché; Alain Larocque; Carine Thiot; Richard Béliveau; Jean-Michel Longpré; Éric Marsault; Richard Leduc; Jean E Lachowicz; Steven L Gonias; Jean-Paul Castaigne; Philippe Sarret
Journal:  J Clin Invest       Date:  2014-02-17       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.